DK0981607T3 - Modificeret arginin-deiminase - Google Patents
Modificeret arginin-deiminaseInfo
- Publication number
- DK0981607T3 DK0981607T3 DK98922197T DK98922197T DK0981607T3 DK 0981607 T3 DK0981607 T3 DK 0981607T3 DK 98922197 T DK98922197 T DK 98922197T DK 98922197 T DK98922197 T DK 98922197T DK 0981607 T3 DK0981607 T3 DK 0981607T3
- Authority
- DK
- Denmark
- Prior art keywords
- arginine deiminase
- modified arginine
- methods
- modified
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03006—Arginine deiminase (3.5.3.6)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4620097P | 1997-05-12 | 1997-05-12 | |
US09/023,809 US6183738B1 (en) | 1997-05-12 | 1998-02-13 | Modified arginine deiminase |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0981607T3 true DK0981607T3 (da) | 2006-12-11 |
Family
ID=26697638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98922197T DK0981607T3 (da) | 1997-05-12 | 1998-05-12 | Modificeret arginin-deiminase |
Country Status (14)
Country | Link |
---|---|
US (3) | US6183738B1 (da) |
EP (1) | EP0981607B1 (da) |
JP (1) | JP4456184B2 (da) |
CN (1) | CN1169951C (da) |
AT (1) | ATE335814T1 (da) |
AU (1) | AU724907B2 (da) |
CA (1) | CA2288948C (da) |
CY (1) | CY1105758T1 (da) |
DE (1) | DE69835515T2 (da) |
DK (1) | DK0981607T3 (da) |
ES (1) | ES2270515T3 (da) |
PT (1) | PT981607E (da) |
TW (1) | TW368504B (da) |
WO (1) | WO1998051784A1 (da) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
US6635462B1 (en) | 1997-05-12 | 2003-10-21 | Phoenix Pharmacologies, Inc. | Mutated form of arginine deiminase |
US5985263A (en) * | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
CN1328152A (zh) * | 2000-06-14 | 2001-12-26 | 上海博德基因开发有限公司 | 一种新的多肽——人nrd转化酶10.01和编码这种多肽的多核苷酸 |
US20040096437A1 (en) * | 2000-07-27 | 2004-05-20 | Bon-Hong Min | Pharmaceutical composition comprising arginine deiminasa for inhibiting angio-genesis |
AU2001275810A1 (en) * | 2000-07-27 | 2002-02-13 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
KR20040004449A (ko) * | 2000-11-28 | 2004-01-13 | 휘닉스 파머컬러직스, 인크. | 변형된 아르기닌 데이미나제 |
US20050063942A1 (en) * | 2001-02-02 | 2005-03-24 | Clark Mike A. | Methods for predicting sensitivity of tumors to arginine deprivation |
US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7696163B2 (en) * | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
WO2004099231A2 (en) * | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7173003B2 (en) * | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7399613B2 (en) * | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7416858B2 (en) * | 2001-10-10 | 2008-08-26 | Neose Technologies, Inc. | Pharmaceutical compositions of glycoconjugates |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7179617B2 (en) * | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
CN100405906C (zh) * | 2002-10-09 | 2008-07-30 | 尼奥斯技术有限公司 | 促红细胞生成素:促红细胞生成素的重构和糖缀合 |
CA2506244C (en) * | 2002-11-18 | 2012-10-30 | Phoenix Pharmacologics, Inc. | Methods for inhibiting viral replication in vivo |
JP4490290B2 (ja) * | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ,コーポレイション | 加水分解安定性マレイミド末端ポリマー |
US7329721B2 (en) | 2002-12-31 | 2008-02-12 | Nektar Therapeutics Al, Corporation | Maleamic acid polymer derivatives and their bioconjugates |
US7432331B2 (en) * | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
JP2006523211A (ja) * | 2003-03-14 | 2006-10-12 | ネオス テクノロジーズ インコーポレイテッド | 分岐水溶性ポリマーとその複合物 |
CN100522988C (zh) * | 2003-04-09 | 2009-08-05 | 诺和诺德公司 | 糖peg化方法及由该方法生产的蛋白质/肽 |
EP1613261A4 (en) * | 2003-04-09 | 2011-01-26 | Novo Nordisk As | INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
BRPI0410164A (pt) | 2003-05-09 | 2006-05-16 | Neose Technologies Inc | composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
CA2547140A1 (en) * | 2003-11-24 | 2005-06-09 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) * | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) * | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US7956032B2 (en) * | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7790835B2 (en) * | 2003-12-03 | 2010-09-07 | Nektar Therapeutics | Method of preparing maleimide functionalized polymers |
EP1694274B1 (en) * | 2003-12-03 | 2013-04-24 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
US8361961B2 (en) * | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
US9085659B2 (en) | 2004-05-03 | 2015-07-21 | Nektar Therapeutics | Polymer derivatives comprising an imide branching point |
RU2006138181A (ru) | 2004-05-04 | 2008-06-10 | Ново Нордиск Хелс Кеа Аг (Ch) | О-связанные гликоформы полипептидов и способ их изготовления |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
CN1745847A (zh) * | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
EP1799249A2 (en) * | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
WO2006035057A1 (en) * | 2004-09-29 | 2006-04-06 | Novo Nordisk Health Care Ag | Modified proteins |
PL2586456T3 (pl) | 2004-10-29 | 2016-07-29 | Ratiopharm Gmbh | Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF) |
JP2008526864A (ja) * | 2005-01-06 | 2008-07-24 | ネオス テクノロジーズ インコーポレイテッド | 糖断片を用いる糖結合 |
EP2514757A3 (en) | 2005-01-10 | 2014-03-05 | ratiopharm GmbH | Glycopegylated granulocyte colony stimulating factor |
JP2008538181A (ja) * | 2005-03-30 | 2008-10-16 | ネオス テクノロジーズ インコーポレイテッド | 昆虫細胞系において増殖させたペプチドを生産するための製造方法 |
EP1871795A4 (en) * | 2005-04-08 | 2010-03-31 | Biogenerix Ag | COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE |
FR2884717B1 (fr) * | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
EP1888098A2 (en) * | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
DE602006013151D1 (de) | 2005-07-19 | 2010-05-06 | Nektar Therapeutics | Verfahren zur herstellung von polymermaleimiden |
US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
CN102719508A (zh) * | 2005-08-19 | 2012-10-10 | 诺和诺德公司 | 糖基聚乙二醇化的因子vii和因子viia |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
US7982010B2 (en) * | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US7985839B2 (en) * | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
EP2010222A1 (en) | 2006-03-31 | 2009-01-07 | Baxter International Inc. | Pegylated factor viii |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US9187532B2 (en) * | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
US20100075375A1 (en) * | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
PT2068907T (pt) * | 2006-10-04 | 2018-01-15 | Novo Nordisk As | Açúcares e glicopéptidos peguilados ligados a glicerol |
WO2008073620A2 (en) * | 2006-11-02 | 2008-06-19 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
EP2101821B1 (en) | 2006-12-15 | 2014-08-13 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
KR20150064246A (ko) * | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 g―csf를 이용하는 치료 방법 |
US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
US20080292609A1 (en) * | 2007-05-21 | 2008-11-27 | Ning Man Cheng | Use of Arginase in Combination with 5FU and Other Compounds for Treatment of Human Malignancies |
CN101778937A (zh) * | 2007-06-04 | 2010-07-14 | 诺和诺德公司 | 使用n-乙酰葡糖胺转移酶的o-联糖基化 |
EP2170919B8 (en) * | 2007-06-12 | 2016-01-20 | ratiopharm GmbH | Improved process for the production of nucleotide sugars |
FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
US8207112B2 (en) * | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CA2711503A1 (en) * | 2008-01-08 | 2009-07-16 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
WO2009108806A1 (en) | 2008-02-27 | 2009-09-03 | Novo Nordisk A/S | Conjugated factor viii molecules |
WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
WO2010023195A2 (en) | 2008-08-26 | 2010-03-04 | Kyon Biotech Ag | Compositions and methods for treating cancer |
US20100150949A1 (en) * | 2008-12-16 | 2010-06-17 | Oncopharmacologics, Inc. | Methods and compositions for modulating proline levels |
CN104530182A (zh) | 2009-07-27 | 2015-04-22 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
AU2010281453C1 (en) * | 2009-07-27 | 2019-08-15 | Takeda Pharmaceutical Company Limited | Blood coagulation protein conjugates |
SG178051A1 (en) | 2009-07-27 | 2012-03-29 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
EP2295560A1 (en) | 2009-09-14 | 2011-03-16 | RWTH Aachen University | Directed evolution of arginine deiminase for increased activity at physiological pH |
CA2782444C (en) | 2010-02-04 | 2018-10-23 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof |
CN101812438B (zh) * | 2010-03-25 | 2014-08-27 | 江苏泰康生物医药有限公司 | 一种精氨酸脱亚氨酶突变体及其制备与应用 |
US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
EA032056B1 (ru) | 2010-12-22 | 2019-04-30 | Баксалта Инкорпорейтид | Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты) |
AU2012330497B2 (en) * | 2012-04-04 | 2016-08-04 | Polaris Group | Methods of treating with arginine deiminase |
WO2014001956A2 (en) * | 2012-06-25 | 2014-01-03 | Ning Man Cheng | Combinational use of pegylated recombinant human arginase with chemotherapeutic/target therapeutic drug in cancer treatment |
US9255262B2 (en) | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
CA2901795C (en) * | 2013-03-15 | 2022-08-02 | Polaris Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
EP3052116B1 (en) | 2013-10-04 | 2021-05-05 | Ann, David K. | Arginase i, arginase ii, or adi in combiantion with doxorubicin for use in a treatmnt of a breast cancer |
TWI676683B (zh) * | 2014-03-14 | 2019-11-11 | 開曼群島商瑞華藥業集團 | 用於癌症治療之對adi-peg20抗體交叉反應性降低之精胺酸去亞胺酶 |
KR102353046B1 (ko) | 2014-03-18 | 2022-01-19 | 티디더블유 그룹 | 조작된 키메라성 페길화된 adi 및 사용 방법 |
CN103923898A (zh) * | 2014-04-17 | 2014-07-16 | 江南大学 | 一种peg修饰的重组精氨酸脱亚胺酶及其制备方法和应用 |
WO2016007625A1 (en) | 2014-07-08 | 2016-01-14 | Tdw Group | Antibodies to argininosuccinate synthase and related methods |
JP6782230B2 (ja) | 2014-09-16 | 2020-11-11 | ティーディーダブリュー グループ | 癌治療のためのadi−peg20抗体に対する交差反応性が低減したアルギニンデイミナーゼ |
CN104726478A (zh) * | 2015-03-09 | 2015-06-24 | 武汉远大弘元股份有限公司 | 表达精氨酸脱亚胺酶基因的重组大肠杆菌及其应用 |
WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
TWI784982B (zh) * | 2016-11-02 | 2022-12-01 | 開曼群島商北極星藥業集團股份有限公司 | 聚乙二醇化精胺酸脫亞胺酶之調配物 |
CN106591271B (zh) * | 2017-03-02 | 2019-07-16 | 江南大学 | 一株酶活和温度稳定性提高的精氨酸脱亚胺酶突变体及其应用 |
WO2019042628A1 (en) | 2017-08-31 | 2019-03-07 | Erytech Pharma | ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY |
EP3449935A1 (en) | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
CA3101667A1 (en) * | 2018-05-31 | 2019-12-05 | The Hong Kong Polytechnic University | Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities |
CN118497178A (zh) * | 2023-02-15 | 2024-08-16 | 重庆派金生物科技有限公司 | 精氨酸脱亚胺酶突变体、共价二聚体及其偶联物和应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US5447722A (en) | 1983-12-12 | 1995-09-05 | University Of Manitoba | Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals |
DE3678702D1 (de) * | 1985-12-28 | 1991-05-16 | Ohgen Research Lab Ltd | Antitumorprotein-gen von streptococcus pyogenes su, plasmide, die das gen enthalten, transformantenzellen, die die plasmide beherbergen, und verfahren zur herstellung des antitumorproteins. |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
JPH0253490A (ja) | 1988-08-16 | 1990-02-22 | Agency Of Ind Science & Technol | アルギニン・デイミナーゼ遺伝子 |
WO1990005534A1 (en) | 1988-11-23 | 1990-05-31 | Genentech, Inc. | Polypeptide derivatives |
JP2900279B2 (ja) | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
JP2736145B2 (ja) | 1990-01-11 | 1998-04-02 | 関東電化工業株式会社 | パーハロゲン化エチレンの製造法 |
JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
JP3209338B2 (ja) | 1990-09-10 | 2001-09-17 | 株式会社ジャパンエナジー | ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法 |
US5372942A (en) * | 1992-02-10 | 1994-12-13 | Coriell Institute For Medical Research | Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent |
WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
US5695760A (en) | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
US5804183A (en) | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
US6180387B1 (en) | 1997-08-11 | 2001-01-30 | Smithkline Beecham Corporation | Arginine deiminase |
-
1998
- 1998-02-13 US US09/023,809 patent/US6183738B1/en not_active Expired - Lifetime
- 1998-05-12 CN CNB988050668A patent/CN1169951C/zh not_active Expired - Lifetime
- 1998-05-12 TW TW087107257A patent/TW368504B/zh not_active IP Right Cessation
- 1998-05-12 EP EP98922197A patent/EP0981607B1/en not_active Expired - Lifetime
- 1998-05-12 DE DE69835515T patent/DE69835515T2/de not_active Expired - Lifetime
- 1998-05-12 DK DK98922197T patent/DK0981607T3/da active
- 1998-05-12 ES ES98922197T patent/ES2270515T3/es not_active Expired - Lifetime
- 1998-05-12 AT AT98922197T patent/ATE335814T1/de active
- 1998-05-12 JP JP54937598A patent/JP4456184B2/ja not_active Expired - Lifetime
- 1998-05-12 PT PT98922197T patent/PT981607E/pt unknown
- 1998-05-12 WO PCT/US1998/009575 patent/WO1998051784A1/en active IP Right Grant
- 1998-05-12 AU AU74798/98A patent/AU724907B2/en not_active Expired
- 1998-05-12 CA CA002288948A patent/CA2288948C/en not_active Expired - Lifetime
-
2000
- 2000-11-28 US US09/723,546 patent/US6737259B1/en not_active Expired - Lifetime
-
2004
- 2004-01-15 US US10/757,843 patent/US7323167B2/en not_active Expired - Lifetime
-
2006
- 2006-11-03 CY CY20061101590T patent/CY1105758T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO1998051784A1 (en) | 1998-11-19 |
DE69835515D1 (de) | 2006-09-21 |
ES2270515T3 (es) | 2007-04-01 |
AU724907B2 (en) | 2000-10-05 |
CA2288948A1 (en) | 1998-11-19 |
JP4456184B2 (ja) | 2010-04-28 |
AU7479898A (en) | 1998-12-08 |
EP0981607A1 (en) | 2000-03-01 |
ATE335814T1 (de) | 2006-09-15 |
US20050129706A1 (en) | 2005-06-16 |
US6737259B1 (en) | 2004-05-18 |
JP2001524836A (ja) | 2001-12-04 |
US7323167B2 (en) | 2008-01-29 |
US6183738B1 (en) | 2001-02-06 |
EP0981607B1 (en) | 2006-08-09 |
EP0981607A4 (en) | 2004-09-01 |
CN1255944A (zh) | 2000-06-07 |
PT981607E (pt) | 2006-11-30 |
CA2288948C (en) | 2007-10-30 |
DE69835515T2 (de) | 2007-08-09 |
CY1105758T1 (el) | 2010-12-22 |
TW368504B (en) | 1999-09-01 |
CN1169951C (zh) | 2004-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0981607T3 (da) | Modificeret arginin-deiminase | |
ES2162681T3 (es) | Conjugados de acido cis-docosahexaenoico y paclitaxel. | |
EA199801031A1 (ru) | Ингибиторы протеинфарнезилтрансферазы | |
CY1107637T1 (el) | Θεραπευτικη αγωγη καρκινου προστατη με αντισωματα αντι - erbb2 | |
TR200103216T2 (tr) | Pirimidinon bileşimleri | |
WO2002044360A3 (en) | Modified arginine deiminase | |
DK0986382T3 (da) | RAF-kinasehæmmere | |
DK0914116T3 (da) | Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere | |
DK1187632T3 (da) | Behandling med anti-ErbB2-antistoffer | |
ES2146774T3 (es) | Polimeros de ioneno que contienen aniones biologicamente activos. | |
UA66793C2 (uk) | Лептин як стримувач швидкого збільшення пухлини клітини | |
BR9912327A (pt) | Inibidores da uroquinase | |
ATE239509T1 (de) | Konjugate zur behandlung von prostatakrebs | |
ATE255632T1 (de) | Immortalisierung bzw. desimmortalisierung von zellen | |
ATE277943T1 (de) | Trypsininhibitoren | |
TR200101756T2 (tr) | Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller. | |
DE69915486D1 (de) | Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne | |
TR200200169T2 (tr) | IL-18 inhibitörlerinin kullanımı. | |
BR0114884A (pt) | Compostos calcilìticos | |
TR199700688A2 (xx) | �yile�tirilmi� �zelliklere sahip aprotinin varyantlar�. | |
TR200003203T2 (tr) | Karboksaldehitin saflaştırılması | |
ATE255594T1 (de) | Hepatitis b inhibitoren | |
DE60143023D1 (de) | Tumorhemmende nitroacridin-zusammensetzungen | |
DK1017377T3 (da) | Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande | |
TR200103662T2 (tr) | Yeni kalpainler ve bunların kullanılması |